Home / Transcripts / IRIDEX Corporation (IRIX) · November 11, 2025

IRIDEX Corporation (IRIX) Earnings Call Transcript

November 11, 2025

NASDAQ US Health Care Health Care Equipment and Supplies earnings 16 min

Earnings Call Speaker Segments

Trip Taylor executive
#1

Good afternoon, and thank you all for joining us today. Joining me from the company are Patrick Mercer, who serves as Iridex's Chief Executive Officer, and Romeo Dizon, the company's Chief Financial Officer. Earlier today, Iridex released its financial results for the quarter ending September 27th, 2025. The press release is available on the company's website. Before we begin, please note that during this call, management will make statements containing forward-looking statements under federal securities laws, issued in reliance on the safe harbor protections of the Private Securities Litigation Reform Act of 1995. Some of what we say today won't be about things that have already happened. That includes remarks about where we're headed strategically, what we're prioritizing, what's happening with our products, how sales are trending, and the sectors we compete in. Everything we say about the future rests on what we currently believe and a range of assumptions. There are meaningful risks and unknowns tied to these remarks, and because of them, real outcomes or events could end up quite different from what we've anticipated or hinted at. So you shouldn't treat any of it as something to count on. If you want to understand the risks and uncertainties our business faces, take a look at the latest Form 10-K and Form 10-Q we've filed with the SEC. Iridex says it has no plan or duty to refresh or amend any financial forecasts or forward-looking remarks—unless the law demands it—regardless of whether fresh details emerge, later occurrences happen, or circumstances change in some other way. What's discussed on this call is tied to a specific moment and holds true solely at the point of today's live transmission, November 11th, 2025. Having said that, I'll pass things along to Patrick.

Patrick Mercer executive
#2

Good afternoon, everyone, and thanks for being with us today. I'm glad to be here to talk through what we delivered in the third quarter. We feel good about the consistent strides we've taken since I stepped into the CEO role a year ago, and across the last 4 quarters, we've carried out our plan to simplify how we operate and move Iridex closer to profitability. Proof of this business's financial makeover shows up in 4 straight quarters of revenue growth compared with the same period a year earlier, along with lower operating expenses and better Adjusted EBITDA. We remain on course to reach positive cash flows during the fourth quarter as well as positive Adjusted EBITDA for the entirety of 2025. Just as important, what we've achieved through the hard work of the past year positions us to also reach cash flow positive operations in 2026. It makes me proud to say that the targets we established for Iridex when this transformation began have now been met. Now, looking at the third quarter in particular, we posted robust revenue growth of 8% over the prior year period. We managed that while cutting operating expenses by 12% and lifting Adjusted EBITDA by $1.3 million versus the same period a year ago. As you may remember, early in the fourth quarter of 2024, we put a set of focused cost-cutting programs into place, and those have brought operating expenses down all through 2025; across the nine months that ended September 27th, operating expenses came down by 25%; these steps have substantially lowered our cash flow needs and made the company's overall financial position stronger, since our cost structure now aligns better with our revenues; we've spotted further chances to make the company's financial profile even stronger and are currently putting actions in motion to boost our gross margins and bring operating expenses down even more. On the manufacturing side, we're in talks with contract manufacturers that might lower our cost of goods sold and help gross margins. Getting these new relationships up and running and moving certain product lines over will take a while, but this is something we're still very enthusiastic about for 2026. In the near term, we're shifting some general and administrative functions out of California; just this step is anticipated to produce roughly $165,000 in savings each quarter starting in the first quarter of 2026; these actions show how committed we are to ongoing cost discipline and better financial performance. Now moving on to how we performed commercially, I'm happy to report that during the third quarter, our top-line revenue rose a solid 8% year-over-year, reaching $12.5 million. Even with a leaner sales force and less spending on marketing, the strong execution from our commercial team has been genuinely remarkable. They keep finding ways to work more efficiently, using technology and long-standing customer relationships to generate sales. Growth in both our Glaucoma and Retina product lines fueled the third quarter's revenue gain. Beginning with our Glaucoma business, we stay excited about the worldwide growth opportunity as more customers embrace our treatment solutions. Within the U.S., our approach for the G6 system focuses on using our large installed base to push system utilization higher. The Medicare LCDs that came out last year have opened up fresh chances to adopt the G6 treatment sooner in the care continuum, for patients in mild to moderate stages. Tactically speaking, we keep leveraging MedScout, which is a sales enablement platform, to spot accounts sitting in the middle range of utilization and help them push their utilization higher. Such practices have already shown a solid dedication to G6, and through focused engagement, we foresee substantial room to grow their procedure volumes. All in all, across the third quarter, sales of the Cyclo G6 system rose to 30 units, up from 26 during the same period a year earlier. The majority of those units went to current users picking up extra systems, frequently because they were opening new sites. We think this shows that clinicians recognize TLT as a treatment option they need. We moved 14,900 probes, versus 13,600 a year earlier, which means better utilization both within the U.S. and abroad; we have also seen a rise in ASPs for probes as well as consults. International Glaucoma results were robust, contributing positively across every geography. Across Europe, the Middle East, and Africa, Glaucoma probe sales kept climbing, helped by filling several orders that had originally been pushed back from Q2 because of supply constraints Iridex faced during the previous quarter. At GMBH, G6-P robe sales stay on a consistent upward path, mirroring ongoing procedural demand and dependable recurring revenue streams. Turning to Asia, for a second straight quarter, that region dealt with volatility and operational difficulties. Although demand stays solid, a number of macro factors keep dragging on our commercial activity. As we had expected in Q2, the continuing tariff dispute with China went on disrupting sales planning and forecasting through Q3. Japan's market stays weak, pushed down by the yen's softness versus the U.S. dollar, which favors domestic rivals who have less exposure to currency swings. Now looking at Latin America and Canada, we enjoyed better G6 business momentum after appointing new Glaucoma distributors and getting a bigger push from partners already in place. Moving over to our Retina product portfolio, here our leading priorities involve pushing wider adoption of our flagship PASCAL system and obtaining further international regulatory approvals for our next-generation Retina platforms, which lets us take advantage of a strong global distribution network. Within the U.S., PASCAL sales stay robust, with sales representatives putting more and more of their effort into promoting our next-generation PASCAL platform. Medical and Surgical Retina revenue climbed by over 10% year-over-year, matching expectations and mirroring consistent market demand. EndoP robe sales held steady all quarter long, showing reliable performance throughout our customer base. Now on to international Retina results; across Europe, the Middle East, and Africa, that region keeps beating expectations, mainly fueled by strong PASCAL results in the Middle East and Africa, together with steady synthesis activities from European markets. MDR certification for the Iridex PASCAL is hurting Retina sales across Europe, yet we expect this and anticipate that pent-up demand will deliver a tailwind once certification comes through. Within GMBH, our capital equipment sales encountered a downturn in operations, driven mostly by delays from purchase shortages tied to that region's summer holiday. Over in Asia, the Retina business took a hit from those same regional forces weighing on Glaucoma, among them the ongoing effects of the tariff dispute with China along with competitive pressure in Japan coming from currency movements. Even with those headwinds, demand underneath for Retina products stays strong. Turning to Latin America and Canada, that region is displaying recovery signals, chiefly powered by a PASCAL sales rebound backed by refreshed distribution engagement. With that, I'll pass the call to Romeo so he can walk through our financial results.

Romeo Dizon executive
#3

Thanks, Patrick. Hi, everyone, and I appreciate you joining us this afternoon. I'd like to begin by going over our financial results for the third quarter, which ended September 27, 2025. As we noted in our press release and as Patrick mentioned, total revenues reached $12.5 million in Q3 2025, an increase of 8% over the prior-year period. That growth was driven primarily by higher sales of Glaucoma probes and PASCAL systems, partially offset by softer surgical Retina probe sales. Retina product revenue climbed 4% year-over-year in Q3 2025, totaling $6.7 million, compared with the third quarter of 2024, driven largely by increased PASCAL system sales as well as medical and surgical Retina system sales, partly offset by lower surgical Retina probe sales. Revenue across all products in the Cyclo G6 Glaucoma group came to $3.5 million, a 13% increase from the prior year. Other revenue rose by $0.2 million, reaching $2.2 million in Q3 2025, compared with $2.0 million in the same quarter of 2024, primarily due to higher service revenue. Gross profit in Q3 2025 was $4.0 million, reflecting a gross margin of 32.1%, which is $0.3 million below the $4.3 million, or 37.3% gross margin, reported in Q3 2024. That gross margin declined 520 basis points, mainly because $0.8 million was charged to cost of goods sold from an inventory write-down, although improved geographic and product mix this year partially offset it. In Q3 2025, we recorded a one-time, non-recurring, non-cash charge to write down inventory following a thorough review related to our transition to a new resource planning system, along with our estimate of unabsorbed raw materials and sub-assembled product costs as we continued shifting production of several product lines to third-party contract manufacturers; we determined those inventories are now excess and obsolete. These stranded costs are typical when production transitions to contract manufacturers. Excluding that one-time write-down, our gross margin rate would have been 38.7%. Operating expenses in Q3 2025 totaled $5.4 million, a decrease of $0.8 million, or 12%, from $6.2 million in Q3 2024, reflecting cost-cutting measures we implemented late in 2024. Consequently, net loss, which includes the one-time charge, was $1.6 million, or $0.09 per share, for Q3 2025, versus a net loss of $1.9 million, or $0.12 per share, in the same quarter last year. Non-GAAP Adjusted EBITDA for Q3 2025 was a loss of $131,000, which is $1.3 million better than the non-GAAP Adjusted EBITDA loss of $1.4 million reported in Q3 2024. That improvement is largely attributable to the expense reduction measures enacted late in 2024. Cash and cash equivalents were $5.6 million at the end of Q3 2025, down $1.2 million from $6.8 million at the close of Q2 2025. Additionally, $37.3 million was mentioned in the context of our overall financial position. The amount of cash we're using has dropped in a good way, and that pleases us — our expectation is that cash usage will stay roughly level at this point or improve. It's clear we're making significant progress, advancing our business plan while focusing far more on profitability. The financial discipline we've maintained is delivering outcomes we're glad to see, and our goal is to hit cash flow break-even in Q4, along with positive EBITDA when fiscal year 2025 comes. With that said, I'll turn it back to Patrick.

Patrick Mercer executive
#4

Thanks, Romeo. If we look back at the last 12 months, we've achieved a great deal in the direction of the targets we set 12 months ago, when I stepped into the CEO position. Above all, it makes us proud that the emphasis we've placed on better operations should help Iridex remain cash flow positive on a continuing basis from here. We keep taking bold steps to bring operating expenses down and to make our financial standing stronger. Iridex is in a strong spot to build on its leadership position in Ophthalmic Laser Systems. To everyone at Iridex, I want to pause and express gratitude for the commitment, the dedication, and the excellent execution you keep showing. We know plenty of you are juggling several responsibilities, and what you bring has certainly been noticed. To those who hold shares in Iridex, we appreciate your ongoing backing; we're eager to bring you an update on how things are going in the next quarter. And to every veteran, Happy Veterans' Day. Thank you for what you've given and for your service.

Operator operator
#5

This concludes today's conference call. Thank you for joining. You may now disconnect.

For developers and AI pipelines

Programmatic access to IRIDEX Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.